Rate My Professor Carolyn Bertozzi

Bertozzi's research focuses on disease-associated glycobiology and the development of therapeutic modalities targeting these pathways through bioorthogonal chemistries for in vivo imaging and bioconjugation. Her inventions include next-generation antibody-drug conjugates, lysosome-targeting chimeras (LYTACs), antibody-enzyme conjugates, and antibody-lectin chimeras, several of which have progressed to clinical candidates for cancer and autoimmune diseases. Key publications comprise "Cell surface engineering by a modified Staudinger reaction" (Science, 2000), "Chemical glycobiology" (Science, 2001), "Copper-free click chemistry for dynamic in vivo imaging" (Proceedings of the National Academy of Sciences, 2007), "A strain-promoted [3+2] azide−alkyne cycloaddition for covalent modification of biomolecules in living systems" (Journal of the American Chemical Society, 2004), and "Bioorthogonal chemistry: fishing for selectivity in a sea of functionality" (Angewandte Chemie International Edition, 2009). She received the 2022 Nobel Prize in Chemistry for bioorthogonal chemistry. Additional honors include the Priestley Medal of the American Chemical Society, Welch Award in Chemistry, Wolf Prize in Chemistry, Heineken Prize, Lemelson-MIT Prize, and MacArthur Fellowship. Bertozzi is an elected member of the National Academy of Sciences, National Academy of Medicine, National Academy of Engineering, American Academy of Arts and Sciences, German Academy of Sciences Leopoldina, and Foreign Fellow of the Royal Society. Her innovations have revolutionized chemical biology, enabling precise interrogation of biomolecules in living organisms and advancing novel therapies.